Lorazepam

Concomitant use may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest.

Apnea, coma, bradycardia, arrhythmia, heart arrest, and death have been reported with concomitant use.

Produces increased CNS-depressant effects including respiratory depression and sedation.

Produces increased CNS-depressant effects including respiratory depression and sedation.

Benzodiazepine that increases sedation intensity and orthostatic hypotension when combined with aripiprazole. Avoid concomitant use.

Produces increased CNS-depressant effects including respiratory depression and sedation.

Rare reports of significant respiratory depression, stupor, and/or hypotension with concomitant use of loxapine and lorazepam.

Additive depression of the central nervous system when administered with lorazepam injection.

Produces increased CNS-depressant effects including respiratory depression and sedation.

Produces increased CNS-depressant effects including respiratory depression and sedation.

Coadministration associated with 55% decrease in lorazepam half-life and 50% increase in volume of distribution, resulting in 3.7-fold increase in plasma concentrations.

Additive depression of the central nervous system when administered with lorazepam injection.

May result in more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Reduce lorazepam dosage by approximately 50%.

Increased incidence of sedation, hallucinations, and irrational behavior observed with concomitant use of injectable lorazepam.

Produces increased CNS-depressant effects including respiratory depression and sedation.

Produces increased CNS-depressant effects including respiratory depression and sedation.

Increases plasma concentrations and reduces clearance of lorazepam. Lorazepam dosage should be reduced by approximately 50%.

May reduce the sedative effects of lorazepam.

Benzodiazepines (e.g., lorazepam) The intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone [see Warnings and Precautions (5.8)] Monitor sedation and blood pressure. 7.2 Drugs Having No Clinically Important Interactions with Aripiprazole Based on pharmacokinetic studies, no dosage adjustment of aripiprazole is required when administered concomitantly with famotidine, valproate, lithium, and lorazepam.

Benzodiazepine that increases sedation intensity and orthostatic hypotension when combined with aripiprazole. Monitor sedation and blood pressure; adjust dose accordingly.

Triazolobenzodiazepines and Other Related Benzodiazepines: Midazolam Alprazolam Triazolam Temazepam Nitrazepam Lorazepam Use With Caution No Dose Adjustment Midazolam : When oral midazolam is co-administered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated [see Warnings and Precautions (5.4) and Pharmacokinetics (12.3) ] . Temazepam, Nitrazepam, Lorazepam : For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.

Eszopiclone and lorazepam decreased each other's Cmax by 22%.

IM lorazepam increases somnolence when combined with IM olanzapine.

Additive effects on cognitive and gross motor functioning observed when co-administered with pregabalin.

Additive effects on cognitive and gross motor functioning when co-administered with pregabalin.

Probenecid increases mean plasma elimination half-life and plasma concentrations of lorazepam; use lower dosages cautiously.

Mild hepatotoxicity has been reported when administered concomitantly with pyrimethamine.

Probenecid inhibits OAT1/3, increasing lorazepam plasma concentrations. Follow recommended lorazepam dosage modifications.

May reduce the sedative effects of lorazepam.

No significant pharmacokinetic interaction observed under steady-state conditions.

No significant pharmacokinetic interaction with duloxetine at steady-state conditions.

No significant pharmacokinetic interaction with duloxetine under steady-state conditions.

No changes in pharmacokinetic parameters for either drug when coadministered. No dosage adjustment necessary.

prednisolone, dexamethasone), cyclosporin, dabigatran( 6 ), delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, edoxaban( 6 ), eslicarbazepine, ethosuximide, everolimus, felbamate, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuximide, midazolam, mirtazapine, nefazodone, nortriptyline, olanzapine, oral and other hormonal contraceptives( 2 ), oxcarbazepine, paliperidone, phenytoin( 3 ), praziquantel, protease inhibitors, quetiapine, risperidone, rivaroxaban( 6 ), sertraline, sirolimus, tadalafil, theophylline, tiagabine, topiramate, tramadol, triazolam, trazodone( 4 ), tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin (5) , ziprasidone, and zonisamide.

Lorazepam Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n = 9) was accompanied by a 17% decrease in the plasma clearance of lorazepam.

7.5 Drugs Without Clinically Significant Interactions with Efavirenz No dosage adjustment is recommended when efavirenz is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lorazepam, nelfinavir, nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, zidovudine), paroxetine, and raltegravir.

7.6 Drugs without Clinically Significant Interactions No dosage adjustment is recommended when efavirenz, lamivudine and tenofovir disoproxil fumarate is administered with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, and lorazepam.

No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline.

Lorazepam : A study of multiple doses of immediate-release fluvoxamine maleate tablets (50 mg given twice daily) in healthy male volunteers (N=12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.

Temazepam Nitrazepam Lorazepam No Dose Adjustment Temazepam, Nitrazepam, Lorazepam : For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.

Concurrent administration of any of the following drugs with lorazepam had no effect on the pharmacokinetics of lorazepam: metoprolol, cimetidine, ranitidine, disulfiram, propranolol, metronidazole, and propoxyphene.

Concurrent administration of any of the following drugs with lorazepam had no effect on the pharmacokinetics of lorazepam: metoprolol, cimetidine, ranitidine, disulfiram, propranolol, metronidazole, and propoxyphene.

Drug Interactions No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.

Lorazepam (IM) — Co-administration of lorazepam does not significantly affect the pharmacokinetics of olanzapine, unconjugated lorazepam, or total lorazepam. However, this co-administration of lorazepam with olanzapine potentiated the somnolence observed with either drug alone.

Concurrent administration of any of the following drugs with lorazepam had no effect on the pharmacokinetics of lorazepam: metoprolol, cimetidine, ranitidine, disulfiram, propranolol, metronidazole, and propoxyphene.

The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol. The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol.

Lorazepam Similar to diazepam.

Lorazepam Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n = 9) was accompanied by a 17% decrease in the plasma clearance of lorazepam.

Lorazepam Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n = 9) was accompanied by a 17% decrease in the plasma clearance of lorazepam.

7.9 Other Concomitant Drug Therapy Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.

7.9 Other Concomitant Drug Therapy Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.

7.9 Other Concomitant Drug Therapy Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.